Amgen Inc (NASDAQ:AMGN)

204.66
Delayed Data
As of 4:00pm ET
 +1.77 / +0.87%
Today’s Change
166.30
Today|||52-Week Range
211.90
+5.13%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$120.4B

Company Description

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Contact Information

Amgen, Inc.
One Amgen Center Drive
Thousand Oaks California 91320-1799
P:(805) 447-1000
Investor Relations:
(805) 447-1060

Employees

Shareholders

Mutual fund holders45.44%
Other institutional33.95%
Individual stakeholders0.90%

Top Executives

There are no executives to display.